Screener
Aardvark Therapeutics, Inc. AARD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$21.59M-132% | -$17.6M-100% | -$16.32M-290% | -$14.37M-164% | -$9.31M-327% | ||
| $11K+120% | $10K+25.0% | $10K+25.0% | $11K+650% | $5K+150% | ||
| $2M+760% | $1.58M+814% | $1.5M+934% | $634K+1,074% | $233K+248% | ||
| -$18.87M-65.7% | -$16.81M-118% | -$16.13M-308% | -$9.84M-134% | -$11.39M-420% | ||
| —— | $0-100% | $4K-20.0% | $91K-2.2% | $0-100% | ||
| $34.25M+130% | —— | —— | —— | -$112.62M-2,252,380% | ||
| $4K-100.0% | $274K— | $171K+167% | $0-100% | $88.88M— | ||
| $15.39M+144% | —— | —— | -$506K-101% | -$35.14M-1,501% |
FAQ
- How much cash does Aardvark Therapeutics, Inc. generate?
- Aardvark Therapeutics, Inc. (AARD) generated -$61.7M in operating cash flow over the trailing twelve months.
- Where does Aardvark Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Aardvark Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.